Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company's mission is to leverage its expertise in metabolism to create innovative therapeutics designed to improve patients' lives.

The company's pipeline includes several drug candidates targeting significant market segments. Its lead program, VK2735, is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, being developed in both subcutaneous and oral formulations for the treatment of obesity and other metabolic disorders. Another key candidate, VK2809, is an orally available, small molecule selective thyroid hormone receptor beta agonist aimed at lipid and metabolic disorders, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Additionally, Viking is developing VK0214 for X-linked adrenoleukodystrophy (X-ALD) and has initiated a new program for dual amylin and calcitonin receptor agonists (DACRAs), with VK3019 entering Phase 1 for obesity.

Under the leadership of President and CEO Brian Lian, Ph.D., Viking Therapeutics reported its first-quarter 2026 financial results on April 29, 2026. The company has fully enrolled its Phase 3 VANQUISH trials for subcutaneous VK2735 in obesity and anticipates initiating a Phase 3 trial for the oral formulation of VK2735 in the fourth quarter of 2026. With a strong cash position of $603 million as of March 31, 2026, Viking is positioned to advance its pipeline in the competitive GLP-1 market, offering both injectable and oral options to address metabolic diseases.